Ensign Peak Advisors Inc Purchases 194,673 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Ensign Peak Advisors Inc raised its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 108.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 374,673 shares of the company’s stock after buying an additional 194,673 shares during the period. Ensign Peak Advisors Inc’s holdings in Nurix Therapeutics were worth $7,059,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in NRIX. Fred Alger Management LLC raised its stake in shares of Nurix Therapeutics by 1.7% during the 4th quarter. Fred Alger Management LLC now owns 168,762 shares of the company’s stock worth $3,179,000 after acquiring an additional 2,748 shares in the last quarter. D. E. Shaw & Co. Inc. increased its stake in shares of Nurix Therapeutics by 54.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 112,841 shares of the company’s stock worth $2,126,000 after acquiring an additional 40,001 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Nurix Therapeutics in the fourth quarter worth $2,337,000. Brevan Howard Capital Management LP purchased a new stake in Nurix Therapeutics during the fourth quarter worth $405,000. Finally, Bank of America Corp DE boosted its holdings in Nurix Therapeutics by 9.3% during the fourth quarter. Bank of America Corp DE now owns 150,935 shares of the company’s stock worth $2,844,000 after buying an additional 12,811 shares in the last quarter.

Nurix Therapeutics Trading Down 4.4%

Shares of NASDAQ:NRIX opened at $9.73 on Wednesday. The company has a market capitalization of $741.78 million, a PE ratio of -3.37 and a beta of 2.23. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56. The firm has a 50 day simple moving average of $11.32 and a 200-day simple moving average of $17.18.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the previous year, the company posted ($0.76) EPS. As a group, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Activity

In other news, insider Gwenn Hansen sold 3,377 shares of the company’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider now directly owns 61,516 shares of the company’s stock, valued at $707,434. This represents a 5.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 6,198 shares of the company’s stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $382,092.92. This trade represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,838 shares of company stock valued at $221,500 in the last ninety days. 7.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

NRIX has been the topic of a number of recent analyst reports. Morgan Stanley increased their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, February 3rd. Royal Bank of Canada raised their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Wells Fargo & Company cut their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. Stephens reiterated an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Finally, Leerink Partners began coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They issued a “market perform” rating and a $16.00 price objective for the company. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $30.44.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.